




















The p53 tumor suppressor protein is arguably the most 
important guardian of the mammalian genome. p53 
promotes longevity by reducing somatic mutations or 
the survival and proliferation of mutant cells. Under 
normal conditions, this proteins role is inconsequential 
because of the rapidity of its degradation. But stress 
signals of almost any form halt the degradation of p53, 
unleashing an active protein that triggers transient cell 
cycle arrest, apoptosis, or cellular senescence [1]. Both 
apoptosis and senescence are potent tumor suppressor 
mechanisms that irreversibly prevent tumorgenesis [2]. 
However, both processes also deplete tissues of 
proliferation-competent progenitor cells, which is a 
characteristic associated with degenerative aging. 
Therefore mammalian survival paradoxically lies at the 
mercy of p53, which oversees a tight balance between 
tumor suppression and long-term cell proliferation.  
 
Almost all human cancers contain impairments in the 
p53 signaling pathway [3]. Roughly one half of cancers 
have inactivating mutations of p53, while the remaining 
half retain function but have miscued activation, 
degradation or cell-cycling. Intense focus on 
understanding p53 regulation at the molecular level has 
led to interest in isolating and developing small-
molecule targets of p53 activity to treat various forms of 
cancer. Nutlins are cis-imidazoline analogs, which 
inhibit the interaction between MDM2 (murine double 
minute 2) and p53, and were discovered by screening a 
chemical library done by Vassilev and colleagues [4]. 
MDM2 negatively regulates p53 by binding to and 
transporting the protein to the cytoplasm where it 























proteosomal degradation.  Nutlins prevent p53-MDM2 
interaction, and thus induce expression of p53-regulated 
genes, which exhibit potent anti-proliferative activities 
(Figure 1A).  
 
Senescence is a complex genetic program and a cell fate 
decision that establishes permanent growth arrest, 
which is a theurapeutic goal in cancer treatment. 
Although there is no direct link between cellular 
senescence and aging, a correlation does exist, as the 
number of senescent cells increases in mammals as they 
age [5]. Activation of p53 is crucial for initiating and 
maintaining senescence in most cell types. However, 
the pro-apoptotic arm of the p53 signaling pathway in 
some senescent cells is dysfunctional [6, 7]. In this issue 
of Aging, Huang et al. explore p53 transcriptional 
activity and apoptosis in senescent human lung 
fibroblasts using nutlin-3. Because nutlin-3 is not 
genotoxic and does not cause p53 phosphorylation or 
deacetylation, it effectively allows investigation of 
downstream p53 signaling in senescent cells.  
 
Senescent cells are characterized by highly compacted 
heterochromatin, termed “senescence-associated hetero-
chromatin foci”, or SAHF [8]. These SAHF are thought 
to lack sites of active gene transcription, as bulk DNA is 
less accessible to the loading of necessary transcription 
factors [9]. Huang et al. observed morphological traits 
typical of senescence in human fibroblast cells (WI-38), 
however, they also noted that basal p53 expression 
levels and target gene activity was normal, or even 
slightly higher. In an attempt to induce p53 transcription 
without affecting upstream signaling, the investigators 
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remain consistent in both early passage and senescent 
WI-38 cells, transcriptional activity of p53 was 
attenuated upon nutlin-3 treatment. Moreover, the 
combined treatment of nutlin-3, together with the DNA 
damaging compound doxorubicin, boosted p53 levels 







































Huang et al. conclude that the decline in p53 
functionality in senescent cells is due to changes in 
upstream signaling that ultimately leads to 
destabilization of p53 and abrogated signaling.  They 
point to the possibility that the pro-apoptotic functions 
of p53 may be redundant in senescent cells, which have 
already lost their ability to proliferate and become 
cancerous.  These findings add to a recent publication 
by this group revealing that nutlin-3 can induce a 
senescence-like state in several epithelial cancer cell 
lines [10], but it is reversible and cells resume 
proliferation upon drug removal and normalization of 
p53 signaling. Perhaps in senescent cells p53 is at a 
balance, coordinating between DNA damage signaling 
and apoptosis. Further studies will be important to help 
identify and optimize therapeutic targets used to treat 
tumor suppression without the downsides associated 
with continual drug treatment or accelerating aging.  
 
The study by Huang and coworkers highlights several 
important issues in cancer therapy development. In 
addition to p53-mediated apoptosis, nutlins may induce 
and maintain a permanent dormancy in cancer cells. 
The ability for nutlin-3 to activate p53 without the 
genotoxic stresses incurred by most chemotherapeutic 
agents is of tremendous clinical importance. It may be 
of value to note that acetylation of p53 also inhibits 
p53-MDM2 interactions [11, 12]. Several recent reports 
have identified the longevity gene, SIRT1, as key 
regulator of p53 acetylation [13-15]. Use of small 
molecule inhibitors of SIRT1, such as Tenovin 6, in 
tandem with nutlins, may provide a double hit on the 
p53 pathway and push the balance toward acetylated 
and activated p53 protein levels sufficient enough to 
induce apoptosis in cancer cells (Figure 1B) [16].  
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